Please assess the completion status of the following clinical trial:

Trial Title: A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of HR+, HER2- metastatic breast cancer (mBC).~* Have all of the following:~  * Recurrent, locally advanced, unresectable or mBC with disease progression following anti-estrogen therapy.~ * Prior treatment with chemotherapy for locally advanced or metastatic disease.~ * No prior treatment with cyclin-dependent kinases (CDK) 4 and 6 inhibitor.~* Have Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1.~* Have discontinued all previous treatments for cancer and recovered from the acute effects of therapy.~* Have adequate organ function.~* Women of child-bearing potential must have a negative pregnancy test.~* Are able to swallow tablets/capsules.~Exclusion Criteria:~* Are currently receiving treatment in a clinical study involving an investigational product.~* Have a serious concomitant systemic disorder.~* Have symptomatic central nervous system (CNS) malignancy or metastasis.~* Have a symptomatic Human Immunodeficiency Virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.~* Have a personal history of syncope of either unexplained or cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest.~* Have a history of any other cancer.~* Had major surgery within 14 days prior to randomization.~* Are breastfeeding.~* Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 200 mg Abemaciclib With a Meal (Type: EXPERIMENTAL): 200 mg abemaciclib given twice a day (BID) orally with a meal.
- 200 mg Abemaciclib Without a Meal (Type: EXPERIMENTAL): 200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.
- 200 mg Abemaciclib Without Regard to Food (Type: EXPERIMENTAL): 200 mg abemaciclib given twice a day (BID) orally without regard for food.

Based on this trial design, predict the completion outcome and termination type (if applicable).